Arcadia Biosciences, Inc. 10-Q

ITEM 5. OTHER INFORMATION Rule 10b5-1 Trading Arrangements During the quarter ended June 30, 2025 , no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K. 31 ITEM 6. E XHIBITS The following exhibits are attached hereto or are incorporated herein by reference. Incorporated by Reference Exhibit Number Exhibit Description Form File No. Exhibit Filing Date Filed Herewith 10.1 First Amendment to Securities Exchange Agreement dated as of April 25, 2025, by and among Arcadia Biosciences, Inc., Roosevelt Resources LP, and Elliot Roosevelt, Jr. and David A. Roosevelt, as Representatives of the Limited Partners 8-K 001-3783 2.1 05/02/2025 31.1 Principal Executive Officer’s Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 X 31.2 Principal Financial Officer’s Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 X 32.1(1) Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 X 32.2(1) Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 X 101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document X 101.SCH Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents X 104.1 Cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, formatted in inline XBRL (and contained in Exhibit 101) X (1) This certification is deemed not filed for purpose of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act. 32 SIGNAT URES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Arcadia Biosciences, Inc. August 14, 2025 By: /s/ THOMAS J. SCHAEFER Thomas J. Schaefer President and Chief Executive Officer August 14, 2025 By: /s/ MARK KAWAKAMI Mark Kawakami Chief Financial Officer 33